JP2016504280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504280A5 JP2016504280A5 JP2015542177A JP2015542177A JP2016504280A5 JP 2016504280 A5 JP2016504280 A5 JP 2016504280A5 JP 2015542177 A JP2015542177 A JP 2015542177A JP 2015542177 A JP2015542177 A JP 2015542177A JP 2016504280 A5 JP2016504280 A5 JP 2016504280A5
- Authority
- JP
- Japan
- Prior art keywords
- atoms
- het
- pharmaceutically acceptable
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 benzoimidazolyl Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000002950 monocyclic group Chemical class 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000002619 bicyclic group Chemical class 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000000038 chest Anatomy 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000011149 active material Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007759.9 | 2012-11-16 | ||
| EP12007759 | 2012-11-16 | ||
| PCT/EP2013/003128 WO2014075754A1 (en) | 2012-11-16 | 2013-10-17 | 3-aminocyclopentane carboxamide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504280A JP2016504280A (ja) | 2016-02-12 |
| JP2016504280A5 true JP2016504280A5 (enExample) | 2016-12-08 |
| JP6316835B2 JP6316835B2 (ja) | 2018-04-25 |
Family
ID=47189693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542177A Expired - Fee Related JP6316835B2 (ja) | 2012-11-16 | 2013-10-17 | ３−アミノシクロペンタンカルボキサミド誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9732032B2 (enExample) |
| EP (1) | EP2920146B1 (enExample) |
| JP (1) | JP6316835B2 (enExample) |
| KR (1) | KR20150085045A (enExample) |
| CN (1) | CN104797553B (enExample) |
| AR (1) | AR093461A1 (enExample) |
| AU (1) | AU2013347232A1 (enExample) |
| BR (1) | BR112015010512A2 (enExample) |
| CA (1) | CA2891484A1 (enExample) |
| ES (1) | ES2608355T3 (enExample) |
| HK (1) | HK1212671A1 (enExample) |
| IL (1) | IL238827A0 (enExample) |
| MX (1) | MX2015006037A (enExample) |
| RU (1) | RU2641913C2 (enExample) |
| SG (1) | SG11201503628YA (enExample) |
| WO (1) | WO2014075754A1 (enExample) |
| ZA (1) | ZA201504323B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016001134A (es) * | 2013-07-29 | 2016-04-29 | Merck Patent Gmbh | Derivados 1,3-disustituidos de ciclopentano. |
| AU2015306643B2 (en) * | 2014-08-28 | 2020-05-07 | X-Chem, Inc. | Soluble epoxide hydrolase inhibitors and uses thereof |
| PE20180572A1 (es) | 2015-06-18 | 2018-04-04 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos |
| EP3310773B1 (en) | 2015-06-18 | 2020-12-02 | 89Bio Ltd. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| US20050053631A1 (en) | 2003-09-10 | 2005-03-10 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Method of decreasing sebum production |
| TWI377198B (en) * | 2005-08-24 | 2012-11-21 | Eisai R&D Man Co Ltd | Novel pyridine derivatives and pyrimidine derivatives (3) |
| EP2307377A1 (en) * | 2008-06-18 | 2011-04-13 | Pfizer Limited | Nicotinamide derivatives |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| ES2463826T3 (es) * | 2009-06-08 | 2014-05-29 | Gilead Sciences, Inc. | Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina |
| EP2491009B1 (en) | 2009-10-19 | 2017-07-05 | Boehringer Ingelheim International GmbH | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| US8450350B2 (en) * | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
-
2013
- 2013-10-17 US US14/442,242 patent/US9732032B2/en not_active Expired - Fee Related
- 2013-10-17 RU RU2015122801A patent/RU2641913C2/ru not_active IP Right Cessation
- 2013-10-17 EP EP13779143.0A patent/EP2920146B1/en not_active Not-in-force
- 2013-10-17 JP JP2015542177A patent/JP6316835B2/ja not_active Expired - Fee Related
- 2013-10-17 CA CA2891484A patent/CA2891484A1/en not_active Abandoned
- 2013-10-17 WO PCT/EP2013/003128 patent/WO2014075754A1/en not_active Ceased
- 2013-10-17 AU AU2013347232A patent/AU2013347232A1/en not_active Abandoned
- 2013-10-17 HK HK16100436.4A patent/HK1212671A1/zh unknown
- 2013-10-17 SG SG11201503628YA patent/SG11201503628YA/en unknown
- 2013-10-17 ES ES13779143.0T patent/ES2608355T3/es active Active
- 2013-10-17 BR BR112015010512A patent/BR112015010512A2/pt not_active IP Right Cessation
- 2013-10-17 CN CN201380059746.3A patent/CN104797553B/zh not_active Expired - Fee Related
- 2013-10-17 MX MX2015006037A patent/MX2015006037A/es unknown
- 2013-10-17 KR KR1020157015816A patent/KR20150085045A/ko not_active Withdrawn
- 2013-11-13 AR ARP130104165A patent/AR093461A1/es unknown
-
2015
- 2015-05-14 IL IL238827A patent/IL238827A0/en unknown
- 2015-06-15 ZA ZA2015/04323A patent/ZA201504323B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529229A5 (enExample) | ||
| JP2015515961A5 (enExample) | ||
| JP2015524450A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2015535831A5 (enExample) | ||
| RU2015115278A (ru) | Производные гидропирролопиррола для применения в качестве ингибиторов синтазы жирных кислот | |
| JP2015509512A5 (enExample) | ||
| JP2011530545A5 (enExample) | ||
| AR078588A1 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
| JP2014509659A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| RU2016137832A (ru) | Соединения для лечения опосредованных комплементом нарушений | |
| JP2020097596A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2010529051A5 (enExample) | ||
| AR091093A1 (es) | Tienopirimidinas | |
| JP2016505512A5 (enExample) | ||
| JP2014512354A5 (enExample) | ||
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| JP2015529234A5 (enExample) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
| JP2018516963A5 (enExample) | ||
| CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
| AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k |